High stakes, low expectations as EU and China prepare for summit in Beijing
The murmurs of a détente that grew in the first quarter have given way to fresh tensions, with the
problems between the two sides multiplying and widening to a surprising degree before Thursday's showdown in the Chinese capital.
In recent months, trade friction and China's support for Russia have resurfaced as flashpoints, dashing any prospect for a feel-good summit.
In a sign of its frustration at how poorly things are going, China cancelled the summit's second day in Hefei, an industrial city in Anhui province where European Commission chief Ursula von der Leyen has family links.
The only deliverable is a joint statement on climate issues, negotiations for which were fraught, but finally concluded overnight on Tuesday, with the text sent to Brussels for the approval of EU ambassadors on Wednesday. Otherwise, the pickings are slim.
Advertisement
'The European deliverable is a substantive, open, direct, good, constructive conversation between the two of us on every aspect of this relationship,' said one official, reflecting just how low the bar has fallen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AllAfrica
6 minutes ago
- AllAfrica
Road to Palestinian state must pass through Saudi Arabia
War makes bystanders feel powerless. Throughout the so-far 22 months of brutal conflict that began with Hamas's slaughter and abduction of Israelis in October 2023, Europeans have looked and felt impotent. This has only partly been because they have also been divided; mainly, it has been because their words, brave or not, proved irrelevant. The question now is whether the decision by France's President Emmanuel Macron to join 11 other EU countries in giving diplomatic recognition to a Palestinian state will be yet another demonstration of European powerlessness and irrelevance. There is a chance that this French initiative could prove different. That chance does not depend much on European unity or disunity, but rather on whether France and others can build a partnership with Arab states, led by Saudi Arabia, that is powerful and determined enough to force Israel and the United States to change course. The chance currently looks a small one, but it may be worth taking. The timing of President Macron's announcement was no accident. On July 28-29, France and Saudi Arabia are scheduled to co-chair a ministerial conference at the United Nations in New York on the Palestinian question, which is intended to be followed by a conference of heads of state in New York in September, alongside the UN General Assembly. The French initiative is intended to inject momentum and an air of diplomatic seriousness into a process that otherwise looked destined to fail. It may still fail. But the small chance that it could make progress depends on France and others convincing the Arab leaders, especially Saudi Arabia's Crown Prince Muhammad bin Salman, that by working together, they might be able to make the Americans take them seriously. Which really depends on Saudi Arabia's crown prince showing the courage and determination to press America's Donald Trump to take the idea of a Palestinian state seriously. The terrible truth about the past 22 months of conflict, chiefly in the Palestinian enclave of Gaza, is that none of the powers involved — neither the Hamas militia, which has governed Gaza since 2006, nor Israel nor Israel's main arms-supplier, the United States — has shown that it cares much about the fate of the roughly 2 million Palestinians living in Gaza nor the roughly 3 million living in the other Palestinian territory occupied by Israel since 1967, known as the West Bank. The 60,000 Palestinians who have died in the conflict have just been seen as collateral damage by everyone concerned. Last week, Israeli and American negotiators withdrew from ceasefire talks with Hamas held in the Arab state of Qatar. It is not yet clear why the talks broke down, but it appears that in return for releasing the 50 remaining Israeli hostages that it holds (of whom 20 are thought to be alive, and 30 dead) Hamas demanded the release by Israel of a large number of Palestinian prisoners. The fact that all sides are delaying a ceasefire over a mere numbers game suggests a lack of seriousness about stopping the fighting. Amid that lack of seriousness, an already deep divide over the idea of a separate Palestinian state has deepened further. The notion of a 'two state solution' to the Israeli-Palestinian conflict dates back many decades, but for a long period beginning in the 1990s it took on an aura of consensus, with the main issue being one of how the Israelis and Palestinians could come to an agreement on borders, on the sensitive status of Jerusalem, and on how the Palestinian state would be governed. However, in recent years, but especially since the October 7, 2023, Hamas attacks, the very idea of a two-state solution has come into question. Previous American administrations, including that of President Joe Biden at the time of Hamas's attacks, had continued to say they were in favor of a Palestinian state even without doing anything serious to advance the idea. But now the Trump administration no longer even talks about it. The divide now is between, on one side, those who argue that creating a sovereign Palestinian state within Gaza and the West Bank represents the only path to a sustainable peace, for it would at last allow Palestinians to govern and police themselves and end their colonial status. And on the other side those, led by the Israeli Prime Minister, Benjamin Netanyahu, who argue that the experience of Gaza shows that a Palestinian state would be a recipe for perpetual war, as it would provide a base from which Hamas-like militias could and would seek to destroy their Israeli neighbors. In reality, both of these propositions contain truth, as does a third proposition, that the status quo of Israeli occupation is itself unsustainable. It is always going to be hard for Israelis and Palestinians to live peacefully alongside each other having fought almost constantly since Israel was founded in 1948, whether in one state or two. The prospect for a more peaceful future must depend on how both states are governed and policed. This is where the rich Arab states, led by Saudi Arabia, could play a crucial role. But it is a role they have sought to avoid until now. If Gaza is to be rebuilt and if any Palestinian state is to be viable, Arab money and intervention will be essential. Yet in the past, the Arabs have been just like the Europeans: powerless bystanders offering words but few actions. Unless and until the United States decides again to promote the idea of a Palestinian state and therefore to pressure Israel to take the idea seriously, there is little prospect of such a state being created. Diplomatic recognition by France, like the earlier recognition by Ireland, Spain and others, will not change the reality, which is that a Palestinian state does not exist. The only thing currently that could stand a chance of changing that reality would be if Saudi Arabia were to make a serious effort to change America's view, perhaps by making the re-adoption of a two-state solution a condition for any other deals Trump wants to make with the Arab states. With their old enemy Iran now severely weakened, this could be a moment when the Saudis feel able to take a diplomatic risk. Which is why President Macron has made his own move, in the hope of strengthening the Saudis' nerve. Other Europeans, including Britain's Sir Keir Starmer and Italy's Giorgia Meloni, should offer him support. The point is worth repeating: it is a small chance, but one that is worth taking. This article first appeared on Bill Emmott's Global View Substack and is republished with kind permission. Read the original here.
South China Morning Post
6 minutes ago
- South China Morning Post
Looming US troop cuts in Europe raise questions about Nato's future
After keeping Donald Trump happy with a pledge to up defence spending at Nato's summit, Europe is now bracing for a key decision from the US president on the future of American forces on the continent. Advertisement Washington is currently conducting a review of its military deployments worldwide – set to be unveiled in the coming months – and the expectation is it will lead to drawdowns in Europe. That prospect is fraying the nerves of US allies, especially as fears swirl that Russia could look to attack a Nato country within the next few years if the war in Ukraine dies down. However, the alliance is basking in Trump's new-found goodwill following its June summit in The Hague, and his officials are making encouraging noises that Europe will not be left in the lurch. 'We've agreed to no surprises and no gaps in the strategic framework of Europe,' said Matthew Whitaker, US ambassador to Nato, adding he expected the review to come out in 'late summer, early fall'. Advertisement 'I have daily conversations with our allies about the process,' he said.
South China Morning Post
6 minutes ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
